Cancer research is research into cancer to identify causes and develop strategies for prevention, diagnosis, treatment, and cure.
Cancer research ranges from epidemiology, molecular bioscience to the performance of clinical trials to evaluate and compare applications of the various cancer treatments. These applications include surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy
and combined treatment modalities such as chemo-radiotherapy. Starting
in the mid-1990s, the emphasis in clinical cancer research shifted
towards therapies derived from biotechnology research, such as cancer immunotherapy and gene therapy.
Cancer research is done in academia, research institutes, and corporate environments, and is largely government funded.
History
Cancer research has been ongoing for centuries. Early research focused on the causes of cancer. Percivall Pott
identified the first environmental trigger (chimney soot) for cancer in
1775 and cigarette smoking was identified as a cause of lung cancer in
1950. Early cancer treatment focused on improving surgical techniques
for removing tumors. Radiation therapy took hold in the 1900s.
Chemotherapeutics were developed and refined throughout the 20th
century.
The U.S. declared a "War on Cancer" in the 1970s, and increased the funding and support for cancer research.
Seminal papers
Some of the most highly-cited and most influential research reports include:
- The Hallmarks of Cancer, published in 2000, and Hallmarks of Cancer: The Next Generation, published in 2011, by Douglas Hanahan and Robert Weinberg. Together, these articles have been cited in over 30,000 published papers.
Types of research
Cancer
research encompasses a variety of types and interdisciplinary areas of
research. Scientists involved in cancer research may be trained in areas
such as chemistry, biochemistry, molecular biology, physiology, medical physics, epidemiology, and biomedical engineering. Research performed on a foundational level is referred to as basic research and is intended to clarify scientific principles and mechanisms. Translational research
aims to elucidate mechanisms of cancer development and progression and
transform basic scientific findings into concepts that can be applicable
to the treatment and prevention of cancer. Clinical research
is devoted to the development of pharmaceuticals, surgical procedures,
and medical technologies for the eventual treatment of patients.
Prevention and epidemiology
Cause and development of cancer
Research into the cause of cancer involves many different disciplines
including genetics, diet, environmental factors (i.e. chemical carcinogens).
In regard to investigation of causes and potential targets for
therapy, the route used starts with data obtained from clinical
observations, enters basic research, and, once convincing and
independently confirmed results are obtained, proceeds with clinical
research, involving appropriately designed trials on consenting human
subjects, with the aim to test safety and efficiency of the therapeutic
intervention method.
An important part of basic research is characterization of the potential
mechanisms of carcinogenesis, in regard to the types of genetic and
epigenetic changes that are associated with cancer development. The
mouse is often used as a mammalian model for manipulation of the
function of genes that play a role in tumor formation, while basic
aspects of tumor initiation, such as mutagenesis, are assayed on
cultures of bacteria and mammalian cells.
Genes involved in cancer
The goal of oncogenomics is to identify new oncogenes or tumor suppressor genes
that may provide new insights into cancer diagnosis, predicting
clinical outcome of cancers, and new targets for cancer therapies. As
the Cancer Genome Project
stated in a 2004 review article, "a central aim of cancer research has
been to identify the mutated genes that are causally implicated in
oncogenesis (cancer genes)." The Cancer Genome Atlas project is a related effort investigating the genomic changes associated with cancer, while the COSMIC cancer database documents acquired genetic mutations from hundreds of thousands of human cancer samples.
These large scale projects, involving about 350 different types of cancer, have identified ~130,000 mutations in ~3000 genes that have been mutated in the tumours. The majority occurred in 319 genes, of which 286 were tumour suppressor genes and 33 oncogenes.
Several hereditary factors can increase the chance of cancer-causing mutations, including the activation of oncogenes or the inhibition of tumor suppressor genes.
The functions of various onco- and tumor suppressor genes can be
disrupted at different stages of tumor progression. Mutations in such
genes can be used to classify the malignancy of a tumor.
In later stages, tumors can develop a resistance to cancer
treatment. The identification of oncogenes and tumor suppressor genes is
important to understand tumor progression and treatment success. The
role of a given gene in cancer progression may vary tremendously,
depending on the stage and type of cancer involved.
Detection
Prompt
detection of cancer is important, since it is usually more difficult to
treat in later stages. Accurate detection of cancer is also important
because false positives can cause harm from unnecessary medical
procedures. Some screening protocols are currently not accurate (such
as prostate-specific antigen testing). Others such as a colonoscopy or mammogram are unpleasant and as a result some patients may opt out. Active research is underway to address all these problems.
One approach is blood screening for a wide variety of tumor markers.
Research published in "Cell" suggests future cancer diagnostics
to be accomplished at an early stage with a single drop of blood.
Treatment
Emerging topics of cancer treatment research include:
- Anti-cancer vaccines
- Oncophage
- Sipuleucel-T (Provenge) is a prostate cancer vaccine
- Newer forms of chemotherapy
- Gene therapy
- Photodynamic therapy
- Radiation therapy
- Reoviridae (Reolysin drug therapy)
- Targeted therapy
- Natural killer cells can induce immunological memory. Research is being developed to modify their action against cancer.
Clinical trials
Research funding
Cancer research is funded by government grants, charitable foundations, and pharmaceutical and biotechnology companies.
In the early 2000s, most funding for cancer research came from
taxpayers and charities, rather than from corporations. In the US, less
than 30% of all cancer research was funded by commercial researchers
such as pharmaceutical companies.
Per capita, public spending on cancer research by taxpayers and
charities in the US was five times as much in 2002-03 as public spending
by taxpayers and charities in the 15 countries that were full members
of the European Union.
As a percentage of GDP, the non-commercial funding of cancer research
in the US was four times the amount dedicated to cancer research in
Europe. Half of Europe's non-commercial cancer research is funded by charitable organizations.
The National Cancer Institute is the major funding institution in the United States. In the 2016 fiscal year, the NCI funded $5.2 billion in cancer research.
Difficulties
Difficulties inherent to cancer research are shared with many types of biomedical research.
Cancer research processes have been criticized. These include,
especially in the US, for the financial resources and positions required
to conduct research. Other consequences of competition for research
resources appear to be a substantial number of research publications
whose results cannot be replicated.
Public participation
One can share computer time for distributed cancer research projects like Help Conquer Cancer. World Community Grid also had a project called Help Defeat Cancer. Other related projects include the Folding@home and Rosetta@home projects, which focus on groundbreaking protein folding and protein structure prediction research.
Members of the public can also join clinical trials as healthy control subjects or for methods of cancer detection.
Dominance of cancer research
Cancer research has grown considerably as indicated by the number of records that have been indexed in the MEDLINE
database, in the 1950s the proportion of cancer-related entries was
approximately 6% of all entries and this has rose to 16% in 2016.
This rise may be attributed to the impact of scientific advances such
as genomics, computing and mathematics, which have had a stronger
influence in Cancer than in other areas such as Cardiovascular
conditions.
Organizations
Organizations exist as associations for scientists participating in cancer research, such as the American Association for Cancer Research and American Society of Clinical Oncology, and as foundations for public awareness or raising funds for cancer research, such as Relay For Life and the American Cancer Society.
Awareness campaigns
Supporters of different types of cancer have adopted different colored awareness ribbons and promote months of the year as being dedicated to the support of specific types of cancer. The American Cancer Society began promoting October as Breast Cancer Awareness Month
in the United States in the 1980s. Pink products are sold to both
generate awareness and raise money to be donated for research purposes.
This has led to pinkwashing, or the selling of ordinary products turned pink as a promotion for the company.